Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News |  Macular Degeneration (AMD) and Diabetic Retinopathy Pharmaceutical Market 2010-2025The global market for AMD & DR drugs exceeded $2.5bn in 2009, with growth from previous years. We predict that the overall market will expand from 2010 onwards. The rising prevalence of AMD & DR is due to aging populations worldwide & other changes.
By: Visiongain Ltd. - what does the future hold for drugs to treat those disorders? Our new report examines current and future prospects for the age-related macular degeneration (AMD) and diabetic retinopathy (DR) pharmaceutical markets. The global market for AMD and DR drugs exceeded $2.5bn in 2009, with growth from previous years. We predict that the overall market will expand from 2010 onwards. The rising prevalence of AMD and DR is due to aging populations worldwide and other changes. In particular, the world is facing a "diabetes epidemic", with soaring numbers of people with diabetes and related complications, including diabetic retinopathy. In particular, Macular Degeneration (AMD) and Diabetic Retinopathy Pharmaceutical Market 2010-2025 covers market prospects for the following agents: • Lucentis • Visudyne • Macugen • Avastin. Our report examines prospects for the retinal disorders market over the coming 15 years. The commercial success of Lucentis in treating wet AMD illustrates the high rewards for successful treatments. Our analyses reveal that there are commercial opportunities for the treatment of geographic atrophy (advanced dry AMD) and for wet AMD, among other disorders. There is a need for advantages over existing therapies, for improved clinical outcomes and ease of dosing. A large potential market for pharmacological treatment of diabetic retinopathy, AMD and other retinal disorders exists. Un-met and under-met therapeutic needs provide an impetus to drug developers, with high technological and commercial potential in this sector, our study reveals. What impact will monoclonal antibodies and steroid implants have on the future market? Which products are most likely to meet therapeutic needs in future years? Can newer therapies compete successfully with established treatments? How will Avastin affect the market share of Lucentis, and what are the implications for the future market? Our new report covers such questions, providing the information that you need. Comprehensive analysis of the global AMD and DR sectors Macular Degeneration (AMD) and Diabetic Retinopathy Pharmaceutical Market 2010-2025 examines those sectors through a comprehensive review of information sources. We harness primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 75 tables and figures included, as well as three interviews with industry experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work. Why you should buy Macular Degeneration (AMD) and Diabetic Retinopathy Pharmaceutical Market 2010-2025 This report gives you the following benefits in particular: • You will receive a comprehensive analysis of the prospects for age-related macular degeneration (AMD) and diabetic retinopathy (DR) drugs from 2010 to 2025, including predicted revenues, growth rates and other data by group and sector • You will receive predicted revenues, growth rates and other data for leading products from 2010 to 2025, with discussions and other supporting information • You will find out the prospects for Lucentis in the face of competition from off-label use of Avastin, with supporting market analyses • You will receive sales forecasts for leading national markets (US, Japan, France, Germany, UK, Spain, Australia, Canada, China and India) from 2010 to 2025 • You will identify R&D pipeline developments and up-and-coming products, with supporting discussions • You will discover the drivers, restraints, competition and opportunities influencing the AMD and DR treatment sectors • You will investigate under-met clinical needs, with therapeutic requirements and commercial opportunities discussed • You will discover expert views from our survey, including full interview transcripts • You will find out where the AMD and DR sectors are heading - technologically and commercially - from 2010 onwards. You can obtain this report today This report is essential reading for anybody interested in the industry and market for treating eye disorders, especially retinal disorders. With expanding patient populations and under-served needs, this sector holds potential for further revenue growth and innovation from 2010 onwards. Our new study reveals prospects for existing competitors and potential market entrants. Do you want to harness those opportunities? Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6 Conatact Person: Bijal Patel bijal.patel@ 0044(0)20 7549 9946 # # # Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
